Profile: Baxter International Inc (BAX.N)
26 May 2017
Baxter International Inc., incorporated on October 19, 1931, through its subsidiaries, provides a portfolio of essential renal and hospital products, including acute and chronic dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; premixed and oncolytic injectables; biosurgery products and anesthetics; drug reconstitution systems, and pharmacy automation, software and services. The Company operates through two segments: Hospital Products and Renal. The Company's products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision. As of December 31, 2016, the Company manufactured products in over 20 countries and sold them in over 100 countries.
The Company's Hospital Products business manufactures sterile IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The business also provides products and services related to pharmacy compounding, and drug formulation; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; premixed and oncolytic injectables; biosurgery products and anesthetics; drug reconstitution systems, and pharmacy automation, software and services. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services.
Baxter International Inc
One Baxter Pkwy, Df2-1W
DEERFIELD IL 60015-4625
Company Web Links
- BRIEF-Third Point LLC dissolves share stake in Apple, Goldman Sachs
- BRIEF-Baxter International says in April became aware of criminal investigation by antitrust division of DOJ- SEC filing
- BRIEF-Baxter International says received guidance from FDA clarifying regulatory pathway for new peritoneal dialysis technology
- BRIEF-Baxter raises quarterly dividend
- BRIEF-Baxter International Q1 revenue $2.5 billion